WAVEMAN · COMPANY

REPL · Replimune Group, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

REPL

Name: Replimune Group, Inc. (REPL) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Replimune Group, Inc.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001737953

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$1.7M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

145

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$1.7M over 180 days

-$1.0M over 90 days

below 64% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

145 funds added or opened last quarter

more than 78% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$1.7M across 6 people in 180 days.

145 funds added or opened positions in the latest 13F quarter, of 201 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +170.8%

+170.8%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $1.7M sold by insiders over 180 days, 145 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Replimune Group, Inc. insiders sold a net $1.7M of stock across 104 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Hill Emily Luisa

Chief Financial Officer

SELL

2026-08-17

9,256.0

$132.2K

Schwendenman Andrew

Chief Accounting Officer

SELL

2026-08-10

7,632.0

$99.0K

Xynos Konstantinos

Chief Medical Officer

SELL

2026-08-10

11,447.0

$148.5K

Hill Emily Luisa

Chief Financial Officer

SELL

2026-08-10

11,448.0

$148.5K

Patel Sushil

Chief Executive Officer

SELL

2026-08-10

39,341.0

$510.3K

104 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 99 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BAKER BROS. ADVISORS LP

11,045,336.0 sh

$122.3M

BlackRock, Inc.

8,958,535.0 sh

$99.2M

RTW INVESTMENTS, LP

7,411,581.0 sh

$82.0M

Ridgeback Capital Investments L.P.

7,310,656.0 sh

$80.9M

GOLDMAN SACHS GROUP INC

4,541,018.0 sh

$50.3M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Horizon Kinetics Medical ETF

$100.9K POSITION · AS OF 2026-03-31

0.6%

Invesco Dorsey Wright SmallCap Momentum ETF

$1.1M POSITION · AS OF 2026-02-28

0.3%

Select Biotechnology Portfolio

$14.3M POSITION · AS OF 2026-02-28

0.3%

State Street(R) SPDR(R) S&P(R) Biotech ETF

$16.8M POSITION · AS OF 2026-03-31

0.2%

PROFUND VP BIOTECHNOLOGY

$93.1K POSITION · AS OF 2026-03-31

0.2%

Virtus Biotech Clinical Trials Etf

$69.7K POSITION · AS OF 2026-04-30

0.2%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2026-03	2025-03	2024-03	2023-03
OPERATING INCOME	$-319.9M	$-261.6M	$-234.8M	$-177.1M
NET INCOME	$-313.9M	$-247.3M	$-215.8M	$-174.3M
EPS (DILUTED)	-3.38	-3.07	-3.24	-2.99
OPERATING CASH FLOW	$-280.3M	$-192.2M	$-185.5M	$-128.1M
CASH	$209.0M	$111.1M	$74.5M	$146.6M
LONG-TERM DEBT	$83.3M	$46.4M	$44.8M	$28.6M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE